ReviewPharmaceuticals (Basel, Switzerland)2010
Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development.
Review in Pharmaceuticals (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management.Current neuropharmacology · 2022Pooled it
- Breath Signatures of Antiseizure Medication Response and Tolerability in Adults With Epilepsy.CNS neuroscience & therapeutics · 2026Observational
- Lithium as a therapeutic strategy for SNAP25 encephalopathies via modulation of homeostatic plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Effect of nerolidol on seizure and oxidative brain damage induced by pentylenetetrazole in mice.Arquivos de neuro-psiquiatria · 2026Article
- Probing the Effects of N-Acetylglucosamine and Diazepam Combination on Oxidative Stress and Epileptogenesis-Associated Genes in Murine Brain.Current issues in molecular biology · 2026Article
- Pretreatment With Methylene Blue Atenuates Seizures, Cognitive Impairment, Hippocampal Neuronal Damage and Oxidative Stress in Pentylenetetrazole-Kindled Rats.Molecular neurobiology · 2026Article
- Association of metabolic disorders and lifestyle behaviors with epilepsy: Evidence from the NHANES database.Medicine · 2025Article
- The nitrergic mechanism of geraniol in PTZ-induced seizures.IBRO neuroscience reports · 2025Article
- Discovery and characterization of phenoxyacetic acid derivatives as potential antiepileptic agents.RSC advances · 2025Article
- Antiepileptic and Neuroprotective Biochemical Actions of Sabinene Prevent the Development of Pentylenetetrazol-Induced Seizures and Neuropsychiatric Comorbidities in Mice.Journal of molecular neuroscience : MN · 2025Article
- Use of Medicinal Cannabis for Epilepsy in the Australian Community 2023-2024: A Cross-Sectional Survey.Journal of epilepsy research · 2025Article
- Resveratrol: A Natural Compound Targeting the PI3K/Akt/mTOR Pathway in Neurological Diseases.Molecular neurobiology · 2025Review
- SCN1A Genetic Alterations and Oxidative Stress in Idiopathic Generalized Epilepsy Patients: A Causative Analysis in Refractory Cases.Indian journal of clinical biochemistry : IJCB · 2025Article
- Antiepileptic profile of Parawixin-11, purified from Parawixia bistriata spider venom (Araneae, Araneidae), in Wistar rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management.CNS & neurological disorders drug targets · 2025Review
- Non-Targeted Screening and Identification of the Transformation Pathway of Carbamazepine in the Saemangeum Watershed, Republic of Korea.International journal of molecular sciences · 2024Article
- Generation and Characterization of Three Novel Mouse Mutant Strains Susceptible to Audiogenic Seizures.Cells · 2024Article
- Review
- Consensus Guideline on the Management of Epilepsy in Egypt: A National Delphi Consensus Study.Epilepsia open · 2024Article
- Tailoring epilepsy treatment: personalized micro-physiological systems illuminate individual drug responses.Annals of medicine and surgery (2012) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a serious neurological disorder that affects around 50 million people worldwide. Almost 30% of epileptic patients suffer from pharmacoresistance, which is associated with social isolation, dependent behaviour, low marriage rates, unemployment, psychological issues and reduced quality of life. Currently available antiepileptic drugs have a limited efficacy, and their negative properties limit their use and cause difficulties in patient management. Antiepileptic drugs can provide only symptomatic relief as these drugs suppress seizures but do not have ability to cure epileptogenesis. The long term use of antiepileptic drugs is limited due to their adverse effects, withdrawal symptoms, deleterious interactions with other drugs and economic burden, especially in developing countries. Furthermore, some of the available antiepileptic drugs may even potentiate certain type of seizures. Several in vivo and in vitro animal models have been proposed and many new antiepileptic drugs have been marketed recently, but large numbers of patients are still pharmacoresistant. This review will highlight the difficulties in treatment and management of epilepsy and the limitations of available antiepileptic drugs and animal seizure models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.